Oral Glucocerebrosidase Activator Cuts α-Synuclein in Parkinson’s
In a groundbreaking advancement that could reshape the therapeutic landscape of Parkinson’s disease, researchers have revealed that a long-term oral glucocerebrosidase activator significantly reduces the...
















